Suzhou’s Innovent Biologics reported that the NMPA accepted the company’s filing of an NDA for its biosimilar to bevacizumab (Avastin). After scoring approvals for two drugs in late 2018 — Tyvyt, a PD-1 drug, and IBI-303, a biosimilar to arthritis treatment Humira — the company has announced three China acceptances of NDA filings in a month. The Avastin biosimilar acceptance is based on clinical data from two clinical studies comparing IBI-305 to the reference drug. Innovent develops novel drugs for oncology, autoimmune and other diseases.
Source: China Biotoday
